A retrospective study of efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with and without interstitial lung disease
Latest Information Update: 07 Jul 2021
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jul 2021 New trial record